QSI stock holds gains as traders eye biotech turnaround. MATT MONACO - UPDATED OCT. 12, 2026, 12:32 PM ET Quantum-Si Incorporated stocks have been trading down by -8.5 percent after discouraging sentiment over its proteomics platform outlook. Key takeaways. * QSI has bounced from below $1 to the mid-$1 range, showing renewed momentum on the daily chart. * Price action in Quantum-Si Incorporated today is consolidating between $1.37 and $1.47 after an early fade. * The latest report shows QSI with over $111.7M in cash and short-term investments and minimal debt, giving the company time to execute. * Quantum-Si Incorporated is still burning cash, with negative free cash flow and steep losses, so traders are focused on runway and dilution risk. * Chart traders are watching whether QSI can build a base above $1.30 and attack recent highs near $1.66. Live Update At 12:32:12 EDT: On Monday, October 12, 2026 Quantum-Si Incorporated stock [NASDAQ: QSI] is trending down by -8.5%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Quantum-Si Incorporated is a classic early-stage, high-burn story that active traders love to dissect. QSI posted just $2.44M in revenue over the trailing period, yet it sports a very high price-to-sales ratio around 208. That tells traders the market is not paying for current sales; it is paying for future potential in QSI's single-molecule protein sequencing platform. Margins are brutal right now. Profitability ratios show an EBIT margin worse than -6,000% and deep negative returns on equity and assets. The latest quarterly numbers show QSI losing about $23.5M with EBITDA around -$21.5M, driven by roughly $15.8M in research and $10M in G&A. This is what aggressive biotech development looks like. The bright spot for Quantum-Si Incorporated is the balance sheet. QSI reports about $111.7M in cash and short-term investments and only about $1.4M in long-term debt. The current ratio near 10 and quick ratio above 9 signal strong short-term liquidity. For traders, that means QSI has meaningful runway to keep funding operations, but the negative free cash flow of roughly -$18.5M per quarter keeps dilution risk on the radar. Why traders are watching QSI price action. Strip away the noise and look at the tape: QSI has quietly doubled off its recent lows. Just a few weeks ago, Quantum-Si Incorporated was printing closes around $0.75-$0.80. Now the daily chart shows closes between $1.22 and $1.55 over the last several sessions, with a recent spike up to roughly $1.66 before pulling back. That kind of move forces traders to pay attention. The latest daily candle for QSI opened at $1.475 and closed at $1.40 after a fade, with a low around $1.37. That tells you early buyers lost control intraday but sellers did not crack the uptrend. On the intraday 5-minute chart, Quantum-Si Incorporated shows heavy premarket trading in the $1.50s, then a gap-down open and a choppy range between $1.38 and $1.45 for most of regular hours. Volume at the open pushed QSI quickly off the highs, then the stock went into a tight consolidation band. For short-term traders, that consolidation matters. Quantum-Si Incorporated is building a battle zone between the prior breakout area near $1.30 and resistance in the mid-$1.60s. If QSI can keep closing above $1.30, it sets up a possible second leg toward $2 on any new catalyst. If it loses $1.20, the whole breakout risks turning into a failed move and potential flush toward the $1.00 level. QSI's fundamentals add another twist. The company has about $180.2M in equity and a book value per share near $0.82, while the stock trades well above that book. Traders in Quantum-Si Incorporated are clearly betting on future execution, not current numbers. Momentum players will keep watching how QSI reacts around prior highs and whether the bid steps in on dips. Conclusion. QSI sits at a classic crossroads that active traders in the Sykes community recognize. The chart for Quantum-Si Incorporated shows a strong bounce off sub-$1 lows, followed by a healthy but uncomfortable pullback and intraday churn. The financials show a cash-rich but loss-making company pushing hard on R&D with negative returns today in hopes of a larger payoff down the road. That mix of high volatility, clear technical levels, and real business risk is what creates opportunity for disciplined traders. Quantum-Si Incorporated has the balance-sheet runway to keep operating, but the steep cash burn and sky-high price-to-sales ratio mean every leg higher comes with serious downside if the story stalls. QSI is not a "set and forget" name; it is a ticker you stalk with a trading plan, key levels, and strict risk rules. Tim Sykes always says, "The market doesn't care about your opinion, only your preparation." As millionaire penny stock trader and teacher Tim Sykes, says, "Small gains add up over time; focus on building wealth gradually, not chasing jackpots.". For QSI, that preparation means knowing the cash runway, understanding the dilution overhang, and mapping the support and resistance that actually control your risk. Quantum-Si Incorporated will reward traders who respect the volatility, cut losses quickly, and treat every move as a lesson, not a promise. This is educational, research-focused trading - nothing more, nothing less. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: Buy this stock for a monster Monday move. Want to start next week off with a big win? Its new algorithm may have just uncovered a new dirt-cheap stock with a great chance of moving +100% or more this Monday. ...One ticker...One trade...One MONSTER move... All you have to do is make this one trade on Monday. While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day. And Millionaire Media, LLC. think this new pick could be just as big. But if Millionaire Media, LLC. is right, it may move FAST... How much has this post helped you? (0 votes, average: 0 out of 5)

Quantum-Si presents interim Proteus(TM) data at World HUPO 2026 demonstrating a significant step change in performance compared to Platinum(R) Pro. All measurable sequencing metrics show profound improvement over Platinum Pro. BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) - Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus(TM) platform with its commercially available Platinum(R) Pro instrument. Using a developmental sequencing kit that detects 18 amino acids, Proteus significantly outperformed Platinum Pro across every key measure, from sequencing scale and accuracy to peptide identification and protein sequence coverage, even though the Proteus instrument, consumable, loading protocol and analysis software are still in development and not yet fully optimized. The data will be presented by Jeff Hawkins, President and Chief Executive Officer, at a lunchtime seminar at the 2026 World HUPO Congress in Singapore on Tuesday, September 29, 2026, at 12:15 Singapore Time (SGT) in Room 330. "These interim results show that Proteus is a fundamentally superior platform technology, not simply a larger version of Platinum Pro," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "Proteus improves every fundamental driver of sequencing performance, including scale, signal quality, conversion and accuracy, and those gains compound into dramatically more data. What makes these results even more encouraging is that this Proteus system has not yet been fully optimized, and we expect further improvements ahead of launch." In a control peptide study designed to evaluate fundamental performance independent of sample preparation, Proteus delivered a median of 30 times more alignments than Platinum Pro from a single chamber, identified all six control peptides in every run, and achieved a 4.8-fold lower median false discovery rate (1.36% in Proteus versus 6.58% in Platinum Pro). Based on these single-chamber results, the Company projects that a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. In protein mixtures prepared with a commercial library prep kit, Proteus identified 1.6 to 2.0 times more peptides than Platinum Pro. Further, in a 24-protein panel not previously sequenced on either platform, Proteus detected all 24 proteins, compared with an average of 20.3 on Platinum Pro, and detected 4.3 times more amino acids per run, with higher per-residue detection across the amino acids measured, including cysteine and histidine, which were detected only on Proteus. A copy of the presentation will be available in the Events & Presentations section of the Quantum-Si investor relations website, and an audio recording will be added once available. Figure 1: Reported alignments per single-chamber run, control peptide study (n = 4 runs per platform) Figure 2: 24-protein panel results from a single chamber, proteins not previously sequenced on either platform About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time, kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products, services and applications, its anticipated cash runway, the anticipated timing of product launches and product capabilities, including the expected launch of Proteus in the second quarter of 2027, the expected performance of Proteus relative to Platinum Pro, including projected full-run performance, and the expected amino acid detection capabilities of Proteus, including the expected detection of all 20 amino acids in the commercial kit at launch, the Company's current belief regarding remaining technical challenges associated with Proteus commercialization, the expected timing and successful completion of system integration, optimization, verification, validation and launch-readiness activities, the expected benefits of the Company's development-process, organizational and cost-control actions, including the reduction in force, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company's ongoing leadership transitions and succession planning; the Company's ability to successfully implement organizational changes, including workforce reductions, cost-control actions and development-process improvements, without disrupting product development, launch readiness, employee retention or customer engagement; the possibility that additional technical, integration, performance, reliability, verification, validation or launch-readiness challenges may arise or take longer or cost more to address than expected; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future, including Proteus; the potential attributes and benefits of the Company's commercialized Platinum Pro protein sequencing instruments and kits and the Company's other products (including Proteus) once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Investor and Media Contact Jeff Keyes Chief Financial Officer [email protected]